![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Takeda to Develop Coronavirus Treatment
Takeda to Develop Coronavirus Treatment
![Test Tubes, computer Screen, testing](https://www.fdanews.com/ext/resources/test/Drug-Images4/test-tubes-computer-screens.gif?t=1584050488&width=430)
Takeda Pharmaceuticals said it will develop a plasma-derived therapy for patients infected with coronavirus.
The drugmaker said it will be developing an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also looking into other products it is developing or marketing that can treat infected patients.
Hyperimmune globulins are plasma derived-therapies that have previously been shown effective for treating severe acute viral respiratory infections.
Upcoming Events
-
18Jul
-
21Oct